Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...

We recently compiled a list of the 10 Best Defensive Stocks According ... The FDA’s late March approval of pulmonary arterial hypertension drug sotatercept, also drove share gains. We retain ...

We recently compiled a list of the 7 Best Stocks for Beginners with Little Money According to Analysts. In this article, we ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

They selected healthcare companies AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and Pfizer ... the loss of patent exclusivity of its top-selling drug. The two successors to Humira, Rinvoq and Skyrizi ...

We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where Merck & Co., Inc ... The market for cancer drugs alone was estimated ...

Merck boasts more than six blockbuster drugs in its portfolio ... You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. However, we believe they may stay invested ...

Merck & Co has axed two hepatitis drugs in its pipeline ... a deep undercutting of Epclusa’s list price of $74,760 for a 12 week course - and analysts think this move could spark a price ...